Reference health

Appropriate Targets for Antibacterial Drugs

CiteStamped reference-health badge
33/33 checkable references clean · checked 2026-08-03

Every reference with a DOI or an arXiv id in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

3 with no DOI or arXiv id: not checked. A reference deposited without a DOI is checked only when it names an arXiv id, under that id’s DataCite DOI. The rest are never matched by title or guessed at; they stay outside the checked set, and this line says so.

The 33 checked references that resolve
resolves10.1016/S1369-5274(00)00133-8
Will genomics revolutionize antimicrobial drug discovery?
resolves10.1016/j.coph.2008.06.008
How many modes of action should an antibiotic have?
resolves10.1021/jm501552x
Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens
resolves10.2174/1568005023342227
Novel Antibacterials: A Genomics Approach to Drug Discovery
resolves10.1101/cshperspect.a025304
Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC
resolves10.1101/cshperspect.a025437
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections
resolves10.1046/j.1365-2958.2002.02832.x
A genome‐wide strategy for the identification of essential genes in <i>Staphylococcus aureus</i>
resolves10.3109/07388559209069193
The Discovery of Cell Wall Active Antibacterial Antibiotics
resolves10.1111/j.1749-6632.2010.05828.x
Challenges of antibacterial discovery revisited
resolves10.2174/1381612023394764
Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
resolves10.1093/jac/dkr466
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens
resolves10.2174/138161207782110408
The Targets of Currently Used Antibacterial Agents: Lessons for Drug Discovery
resolves10.2174/1568005023342597
Antibacterial Drug Discovery in the Post-Genomics Era
resolves10.1111/j.1469-0691.2006.01403.x
Can β-lactams be re-engineered to beat MRSA?
resolves10.1093/jac/dkr262
Discovery research: the scientific challenge of finding new antibiotics
resolves10.1038/ismej.2011.122
Quorum quenching quandary: resistance to antivirulence compounds
resolves10.1046/j.1365-2672.92.5s1.16.x
Novel targets for the future development of antibacterial agents
resolves10.1016/j.bcp.2005.11.025
When will the genomics investment pay off for antibacterial discovery?
resolves10.1007/978-1-4614-1400-1_28
Cell-Based Screening in Antibacterial Discovery
resolves10.1016/j.bcp.2005.11.023
Antibacterial drug discovery—Then, now and the genomics future
resolves10.1128/AAC.47.9.2850-2858.2003
Biological Costs and Mechanisms of Fosfomycin Resistance in <i>Escherichia coli</i>
resolves10.1016/S1359-6446(04)03285-4
Antibiotics: Where did we go wrong?
resolves10.1038/nrd2201
Drugs for bad bugs: confronting the challenges of antibacterial discovery
resolves10.1016/S1471-4892(02)00197-2
New (and not so new) antibacterial targets – from where and when will the novel drugs come?
resolves10.1111/cbdd.12517
Virulence‐targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms
resolves10.1093/genetics/123.4.625
Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium.
resolves10.1038/nrd2202
Multi-targeting by monotherapeutic antibacterials
resolves10.1128/CMR.00030-10
Challenges of Antibacterial Discovery
resolves10.1007/978-1-4614-1400-1_2
Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening
resolves10.1128/AAC.37.3.377
Discovery and development of new antibiotics: the problem of antibiotic resistance
resolves10.1586/eri.11.81
Screening strategies for discovery of antibacterial natural products
resolves10.1038/nrd4572
ESKAPEing the labyrinth of antibacterial discovery
resolves10.1101/cshperspect.a027045
Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics
The 3 references with no DOI or arXiv id, listed, not checked
no DOI — not checkedThe 2012 Garrod Lecture: Discovery of antibacterial drugs in the 21st century
no DOI — not checkedCan resistance against quorum-sensing interference be selected?
no DOI — not checkedBacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. If Crossref’s record marks the work itself retracted, withdrawn, or removed, the badge says so instead of showing clean. It says nothing about the quality, findings, or importance of the work itself, and nothing about references with neither a DOI nor an arXiv id.

checked 2026-08-03 — re-checked at most once a day, when someone opens this page, so the date shown is the last check; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge shows the date of its last check, which runs at most once a day, when someone opens this page.

<a href="https://citestamp.com/citestamped/10.1101/cshperspect.a030239"><img src="https://citestamp.com/citestamped/10.1101/cshperspect.a030239/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1101/cshperspect.a030239/badge.svg)](https://citestamp.com/citestamped/10.1101/cshperspect.a030239)